The role of antibody glycosylation in autoimmune and alloimmune kidney diseases
Top Cited Papers
- 3 July 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 20 (10) , 672-689
Abstract
Immunoglobulin glycosylation is a pivotal mechanism that drives the diversification of antibody functions. The composition of the IgG glycome is influenced by environmental factors, genetic traits and inflammatory contexts. Differential IgG glycosylation has been shown to intricately modulate IgG effector functions and has a role in the initiation and progression of various diseases. Analysis of IgG glycosylation is therefore a promising tool for predicting disease severity. Several autoimmune and alloimmune disorders, including critical and potentially life-threatening conditions such as systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and antibody-mediated kidney graft rejection, are driven by immunoglobulin. In certain IgG-driven kidney diseases, including primary membranous nephropathy, IgA nephropathy and lupus nephritis, particular glycome characteristics can enhance in situ complement activation and the recruitment of innate immune cells, resulting in more severe kidney damage. Hypofucosylation, hypogalactosylation and hyposialylation are the most common IgG glycosylation traits identified in these diseases. Modulating IgG glycosylation could therefore be a promising therapeutic strategy for regulating the immune mechanisms that underlie IgG-driven kidney diseases and potentially reduce the burden of immunosuppressive drugs in affected patients.Keywords
This publication has 330 references indexed in Scilit:
- IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 SamplesArthritis & Rheumatology, 2022
- N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid ArthritisArthritis & Rheumatology, 2019
- Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG GlycomeArthritis & Rheumatology, 2015
- Functional analysis of agalactosyl IgG in inflammatory bowel disease patientsInflammatory Bowel Diseases, 2011
- Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)Arthritis & Rheumatism, 2011
- Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritisArthritis & Rheumatism, 2010
- A close look at human IgG sialylation and subclass distribution after lectin fractionationProteomics, 2009
- Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serumProteomics, 2007
- Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritisJournal of Clinical Laboratory Analysis, 2007
- Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure.The EMBO Journal, 1991